[Dengue fever and dengue hemorrhagic fever].

Laboratory of Vector-borne Viruses, Department of Virology 1, National Institute of Infectious Diseases.
Nippon rinsho. Japanese journal of clinical medicine 04/2007; 65 Suppl 3:117-21. DOI: 10.1016/S1045-1870(97)80003-9
Source: PubMed
1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Dengue fever is the most important vector-borne viral disease. Four serotypes of dengue virus, DENV1 to DENV4, coexist. Infection by one serotype elicits long-lasting immunity to that serotype but not the other three. Subsequent infection by a different serotype is a risk factor for severe dengue. Domain III (ED3) of the viral envelope protein interacts with cell receptors and contains epitopes recognized by neutralizing antibodies. We determined the serotype specificity and cross-reactivity of human IgMs directed against ED3 by using a well-characterized collection of 90 DENV-infected and 89 DENV-uninfected human serums. The recognitions between the four serotypes of ED3 and the serums were assayed with an IgM antibody-capture ELISA (MAC-ELISA) and artificial homodimeric antigens. The results were analyzed with Receiving Operator Characteristic (ROC) curves. The DENV-infected serums contained IgMs that reacted with one or several ED3 serotypes. The discrimination by ED3 between serums infected by the homotypic DENV and uninfected serums varied with the serotype in the decreasing order DENV1 > DENV2 > DENV3 > DENV4. The ED3 domain of DENV1 gave the highest discrimination between DENV-infected and DENV-uninfected serums, whatever the infecting serotype, and thus behaved like a universal ED3 domain for the detection of IgMs against DENV. Some ED3 serotypes discriminated between IgMs directed against the homotypic and heterotypic DENVs. The patterns of cross-reactivities and discriminations varied with the serotype. The results should help better understand the IgM immune response and protection against DENV since ED3 is widely used as an antigen in diagnostic assays and an immunogen in vaccine candidates.
    BMC Infectious Diseases 07/2013; 13(1):302. · 3.03 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Dengue is one of the most important emerging vector-borne viral diseases. There are four serotypes of dengue viruses (DENV), each of which is capable of causing self-limited dengue fever (DF) or even life-threatening dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). The major clinical manifestations of severe DENV disease are vascular leakage, thrombocytopenia, and hemorrhage, yet the detailed mechanisms are not fully resolved. Besides the direct effects of the virus, immunopathological aspects are also involved in the development of dengue symptoms. Although no licensed dengue vaccine is yet available, several vaccine candidates are under development, including live attenuated virus vaccines, live chimeric virus vaccines, inactivated virus vaccines, and live recombinant, DNA and subunit vaccines. The live attenuated virus vaccines and live chimeric virus vaccines are undergoing clinical evaluation. The other vaccine candidates have been evaluated in preclinical animal models or are being prepared for clinical trials. For the safety and efficacy of dengue vaccines, the immunopathogenic complications such as antibody-mediated enhancement and autoimmunity of dengue disease need to be considered.
    Journal of Biomedical Science 06/2013; 20(1):37. · 2.46 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In this paper, we demonstrate an extremely efficient technique of diagnosing dengue virus non-structural protein (NS1) using Micro-Spot with Integrated Pillars (MSIP). Detection using MSIP is performed by employing fluorescence immunoassay specific to dengue virus NS1. MSIPs are chemically modified to ensure efficient covalent binding of antibodies on the micropillars, whereas the enormous increase in the surface area (available for the reaction) induced by the micropillars amplifies the apparent rate, which enhances the signal intensity. Therefore, the detection response of a MSIP, quantified by the intensity of the fluorescence signal, is found to be almost five times magnified than the response of a similar size micro-spot without micropillars. The response of the micropillars also depend on the pillar arrangement, since for identical concentration of dengue NS1 antigen, a stronger intensity signal is obtained for a hexagonal close packed array (staggered) pillar arrangement as compared to a square array arrangement.
    Biomedical Microdevices 07/2013; · 2.72 Impact Factor


Available from